Question Bank › Named counterparty roster suddenly upgraded in c

Named counterparty roster suddenly upgraded in caliber

Calls Tested
500
Answered YES
7
Hit Rate
1.4%
rare by design

ChromaDex Corporation (CDXC) — this company's answers

NO on the Q4 2021 call 2022-03-09 C+
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了“交易对手方质量近期提升”这一发展,且包含三个要素:1)近期发生的质量转变;2)实际当前业务;3)关系仍处于早期阶段。 在记录中,管理层提到了多个合作伙伴:Sinopharm Xingsha(中国大型制药公司子公司)、H&H Group、Ro、Designs for Health、Nestle等。这些合作伙伴的规模或地位较高,但需要确认是否“近期”开始交易,以及是否属于“实际当前业务”且“早期”。 Rob Fried提到:“我们与Sinopharm Xingsha合作……帮助发展跨境业务,并合作获得中国保健食品注册。”以及“我们正在敲定商业计划和供应协议……用于初始跨境销售。”这表明Sinopharm是近期合作,且业务尚在初期。同样,H&H Group和Ro是2021年签署的协议,但H&H尚未推出产品(“H&H将不会在2022年第一季度推出”),Ro可能也在早期。Designs for Health是近期合作(“我们新的战略合作伙伴Designs for Health”),但尚未有具体销售描述。Nestle是既有关系,但管理层提到“正在讨论如何使合作更有影响力”,可能不是新升级。 关键点:管理层是否明确表示这些是“更高等级”的对手方?例如,Sinopharm是“中国最大制药公司之一的子公司”,Designs for Health是“优质膳食补充剂,拥有广泛的医疗保健从业者网络”。这些描述表明其规模或地位较高。但需要确认是否“近期”开始交易,以及是否“实际当前业务”。对于Sinopharm,管理层说“我们正在敲定商业计划和供应协议”,意味着尚未开始实际销售,只是计划中。对于H&H,尚未推出。对于Ro,可能已有销售?记录中未明确。对于Designs for Health,刚签约,可能尚未有收入。 因此,这些合作伙伴中,有些是“近期”签约,但实际业务尚未发生或刚开始。管理层在2022年展望中提到“我们预计新合作伙伴在2021年和Designs for Health在2022年初将带来更有意义的收入贡献”,但这是预期,不是当前实际。此外,管理层提到“我们的展望仅包括现有合作伙伴的收入,不包括潜在新合作伙伴的上升空间”,表明这些合作伙伴的收入已计入预期,但实际发生情况未知。 另外,管理层提到“我们与Nestle的讨论”,但Nestle是既有关系,不是新升级。 综合来看,管理层确实提到了多个大型合作伙伴,但其中一些尚未产生实际收入,或者只是计划中。例如,Sinopharm的供应协议还在敲定,H&H尚未推出,Designs for Health刚签约。因此,可能不符合“实际当前业务”的要求。此外,这些合作伙伴是否比历史常态更高?历史上有Watsons、Monte Cana等,但Sinopharm、H&H等规模更大,但管理层并未明确对比“现在与过去”的对手方等级。 因此,我认为答案应为NO,因为虽然提到了大型合作伙伴,但实际业务尚未发生或处于早期,且未明确对比历史常态。此外,管理层并未明确说“最近开始与更高等级对手方交易”,而是描述了一些新合作,但未强调“升级”。 根据要求,必须三个要素都具备。这里可能缺少“实际当前业务”和“早期相对关系”的明确描述。例如,对于Sinopharm,是“敲定计划”,不是实际业务。对于H&H,是“尚未推出”。所以,答案应为NO。

← Back to the full CDXC analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the CALIBER OF COUNTERPARTIES NOW DOING REAL BUSINESS WITH THE COMPANY HAS RECENTLY STEPPED UP — that customers, partners, or institutions of a size, stature, or sophistication the company did not previously transact with are NOW actually buying, deploying, contracting, or committing — and does management present this upgraded roster as a recent change grounded in current transactions, with the associated business still early relative to what those relationships imply? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) A CALIBER SHIFT, RECENTLY OCCURRED: management conveys — by naming counterparties, by describing their category unmistakably ('one of the largest X', 'a national system', 'a top-tier operator'), or by contrasting who buys now versus who used to — that the company has recently begun transacting with a visibly higher class of counterparty than its historical norm; (2) REAL CURRENT BUSINESS, NOT LOGOS: these upgraded counterparties are actually paying, ordering, deploying, or committing now, described with operating substance, not letters of intent, pilots without payment, or pipeline; and (3) EARLY RELATIVE TO THE RELATIONSHIP: management conveys that what these counterparties have taken so far is the beginning — initial orders, first phases, first deployments — with the fuller relationship still ahead of the reported results. Answer NO if the counterparties described are the same kinds the company has always served. NO if the higher-caliber parties are only prospects, in discussions, or unpaid evaluations. NO if the company is itself large so that big counterparties are unremarkable for it. NO if the relationships are mature and fully reflected in results. NO if the upgrade rests on one anecdote management treats as exceptional. NO if the caliber shift appears only in analyst flattery management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

ASAN · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES The transcript shows management describing a recent caliber shift to higher-tier enterprise counterparties (Fortune 50 companies with tens of thousands of seats, ViacomCBS, Fujitsu, etc.) that are now conducting real business through larger deals, multiyear agreements, and wall-to-wall deployments.
APPS · Q1 2024 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES Management describes a clear caliber shift with SingleTap: first revenues generated with TikTok (a top-tier social platform), launching with LinkedIn (another major social media company), and expecting a revenue-generating pilot with another large social media company.
EVGO · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties has recently stepped up, with real current business that's still early.

More from the question bank

The economics improved before the volume arrGeographic or market replication just starteRegular buyers moved from occasional to progConstraint-side candorManagement describes competitors unable to rPhysical throughput records at the operatingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.